Overview

Combination of PRP and XLHA Prepared With RegenMatrix Medical Device To Treat Moderate to Severe Knee Osteoarthritis

Status:
Not yet recruiting

Trial end date:
2024-08-15

Target enrollment:

Participant gender:

Summary

In this clinical trial the investigator assess the safety and efficacy of a single injection of a combination of cross-linked hyaluronic acid (HA) with autologous platelet-rich plasma (PRP) obtained with the RegenMatrix medical device to improve symptoms of moderate to severe knee osteoarthitis (grade III-IV Kellgren-Lawrence).

Phase:

N/A

Details

Lead Sponsor:

RegenLab France SAS

Treatments:

Hylan